Syngene International Ltd
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations. [1]
- Market Cap ₹ 34,248 Cr.
- Current Price ₹ 851
- High / Low ₹ 946 / 608
- Stock P/E 74.3
- Book Value ₹ 109
- Dividend Yield 0.15 %
- ROCE 14.7 %
- ROE 13.2 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Debtor days have improved from 59.3 to 46.2 days.
Cons
- Stock is trading at 7.79 times its book value
- Company has a low return on equity of 13.5% over last 3 years.
- Dividend payout has been low at 10.3% of profits over last 3 years
- Promoter holding has decreased over last 3 years: -15.7%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Healthcare Industry: Miscellaneous
Part of Nifty 500 Multicap 50:25:25 Nifty 500 BSE 400 MidSmallCap Index Nifty Total Market Nifty MidSmall Healthcare
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|
1,423 | 1,826 | 2,012 | 2,184 | 2,604 | 3,193 | 3,489 | 3,451 | |
949 | 1,289 | 1,394 | 1,507 | 1,806 | 2,251 | 2,472 | 2,488 | |
Operating Profit | 474 | 537 | 618 | 678 | 798 | 942 | 1,017 | 963 |
OPM % | 33% | 29% | 31% | 31% | 31% | 30% | 29% | 28% |
53 | 75 | 153 | 94 | 20 | 63 | 77 | 108 | |
Interest | 23 | 32 | 35 | 28 | 24 | 45 | 47 | 48 |
Depreciation | 131 | 164 | 219 | 274 | 310 | 366 | 426 | 437 |
Profit before tax | 372 | 415 | 517 | 469 | 484 | 594 | 621 | 586 |
Tax % | 18% | 20% | 20% | 14% | 18% | 22% | 18% | |
305 | 332 | 412 | 405 | 396 | 464 | 510 | 482 | |
EPS in Rs | 7.64 | 8.29 | 10.30 | 10.12 | 9.88 | 11.57 | 12.69 | 11.98 |
Dividend Payout % | 7% | 3% | 0% | 0% | 10% | 11% | 10% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | 14% |
3 Years: | 17% |
TTM: | -1% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | 10% |
3 Years: | 11% |
TTM: | -9% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 21% |
3 Years: | 12% |
1 Year: | 18% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | 14% |
3 Years: | 13% |
Last Year: | 13% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|
Equity Capital | 200 | 200 | 400 | 400 | 401 | 401 | 402 | 402 |
Reserves | 1,520 | 1,768 | 1,776 | 2,421 | 2,897 | 3,217 | 3,856 | 3,993 |
787 | 813 | 773 | 893 | 1,022 | 815 | 555 | 637 | |
681 | 922 | 1,214 | 1,169 | 1,245 | 1,398 | 1,339 | 1,104 | |
Total Liabilities | 3,189 | 3,704 | 4,163 | 4,883 | 5,564 | 5,831 | 6,152 | 6,136 |
1,030 | 1,377 | 2,020 | 2,201 | 2,393 | 2,667 | 2,850 | 2,861 | |
CWIP | 155 | 274 | 234 | 237 | 346 | 177 | 838 | 904 |
Investments | 158 | 716 | 776 | 702 | 1,034 | 918 | 548 | 539 |
1,846 | 1,337 | 1,133 | 1,743 | 1,790 | 2,069 | 1,916 | 1,832 | |
Total Assets | 3,189 | 3,704 | 4,163 | 4,883 | 5,564 | 5,831 | 6,152 | 6,136 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
446 | 630 | 677 | 701 | 581 | 824 | 1,042 | |
-349 | -646 | -424 | -629 | -611 | -653 | -494 | |
-79 | -72 | -226 | 58 | -31 | -342 | -552 | |
Net Cash Flow | 18 | -88 | 28 | 130 | -62 | -172 | -4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|
Debtor Days | 68 | 68 | 72 | 79 | 71 | 61 | 46 |
Inventory Days | 82 | 30 | 18 | 41 | 87 | 141 | 94 |
Days Payable | 195 | 154 | 156 | 167 | 113 | 109 | 100 |
Cash Conversion Cycle | -44 | -56 | -66 | -47 | 45 | 92 | 40 |
Working Capital Days | -28 | -65 | -115 | -20 | -3 | -1 | -18 |
ROCE % | 17% | 17% | 14% | 13% | 15% | 15% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
8h - Schedule of meeting with analyst/institutional investor.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
11 Nov - Details of the meeting to be held with the Analyst/Institutional Investor.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
6 Nov - Details of the meeting to be held with the Analyst/Institutional Investor.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
6 Nov - Details of the meeting to be held with the Analyst/ Institutional Investor.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
29 Oct - Intimation of Q2 FY2025 Earnings Call transcript.
Annual reports
Concalls
-
Oct 2024Transcript PPT
-
Jul 2024Transcript PPT REC
-
Jul 2024TranscriptNotesPPT
-
Apr 2024TranscriptPPT
-
Jan 2024TranscriptNotesPPT
-
Jan 2024Transcript PPT
-
Oct 2023Transcript PPT
-
Jul 2023Transcript PPT
-
May 2023Transcript PPT
-
Jan 2023Transcript PPT
-
Oct 2022TranscriptNotesPPT
-
Jul 2022TranscriptNotesPPT
-
Apr 2022TranscriptNotesPPT
-
Jan 2022Transcript PPT
-
Oct 2021Transcript PPT
-
Jul 2021Transcript PPT
-
Apr 2021TranscriptNotesPPT
-
Mar 2021TranscriptPPT
-
Jan 2021TranscriptNotesPPT
-
Oct 2020Transcript PPT
-
Jul 2020Transcript PPT
-
May 2020Transcript PPT
-
Feb 2020TranscriptPPT
-
Jan 2020TranscriptNotesPPT
-
Dec 2019TranscriptPPT
-
Oct 2019Transcript PPT
-
Jul 2019Transcript PPT
-
Apr 2019Transcript PPT
-
Feb 2019Transcript PPT
-
Oct 2018Transcript PPT
-
Jul 2018TranscriptNotesPPT
-
May 2018TranscriptPPT
-
Apr 2018Transcript PPT
-
Jan 2018TranscriptNotesPPT
-
Nov 2017Transcript PPT
-
Aug 2017Transcript PPT
-
May 2017Transcript PPT
-
Jan 2017TranscriptNotesPPT
-
Oct 2016TranscriptNotesPPT
-
Jul 2016TranscriptNotesPPT
-
Feb 2016TranscriptNotesPPT
-
Oct 2015TranscriptPPT
Business Footprint:[1]
The company caters to diverse end-user industries like Pharmaceuticals, Animal Health, Agrochemicals, Consumer Packaged Goods, Chemicals/Polymers.
It has 400+ active customers with engagements with 13 out of the top 15 global pharma companies. The company holds 400+ patents jointly with clients and has a base of 6000+ scientists.